Endocrine Pharmacology Practice Questions

Q: Finasteride has efficacy in the prevention of male pattern baldness by virtue of its ability to:

Reduce the production of DHT. **Explanation:** **Androgenetic Alopecia (AGA)**, or male pattern baldness, is primarily driven by the action of **Dihydrotestosterone (DHT)** on genetically susceptible hair follicles. DHT causes follicular miniaturization, leading to shorter, thinner hair cycles. **Why the correct answer is right:** Finasteride is a selective **Type II 5-alpha reductase inhibitor**. The enzyme 5-alpha reductase is responsible for converting Testosterone into the more potent androgen, DHT. By inhibiting this enzyme, Finasteride significantly **reduces the production of DHT** (by approximately 70% in serum), thereby halting the miniaturization process and promoting hair regrowth. **Why the incorrect options are wrong:** * **Option A:** Drugs that competitively antagonize androgen receptors include **Spironolactone** or **Flutamide**. Finasteride does not block the receptor; it blocks the conversion of the hormone itself. * **Option B:** Gonadotropin release (FSH/LH) is inhibited by **GnRH agonists/antagonists** or combined oral contraceptives. Finasteride does not act on the hypothalamic-pituitary-gonadal axis. * **Option C:** Testosterone synthesis occurs in the Leydig cells of the testes. Finasteride does not stop testosterone production; in fact, it may cause a slight compensatory increase in serum testosterone levels. **High-Yield Clinical Pearls for NEET-PG:** * **Dosing:** For AGA, the dose is **1 mg/day** orally. (Note: 5 mg/day is used for Benign Prostatic Hyperplasia). * **Dutasteride:** A more potent alternative that inhibits **both Type I and Type II** 5-alpha reductase. * **Side Effects:** Potential sexual dysfunction (decreased libido, erectile dysfunction) and a slight risk of gynecomastia. * **Contraindication:** It is strictly contraindicated in **pregnancy** (Category X) as it can cause feminization of a male fetus.

Q: Which among the following is also called "peakless" insulin analog?

Insulin glargine. **Explanation:** **Insulin glargine** is classified as a long-acting basal insulin analog. It is referred to as **"peakless"** because of its unique pharmacokinetic profile. Upon subcutaneous injection, the acidic solution (pH 4.0) neutralizes to physiological pH, causing the insulin to microprecipitate into stable hexamers. These hexamers are released slowly and consistently into the bloodstream, providing a steady, flat concentration for up to 24 hours. This lack of a distinct peak mimics physiological basal insulin secretion and significantly reduces the risk of nocturnal hypoglycemia. **Analysis of Incorrect Options:** * **Insulin lispro & Insulin aspart (Options A & C):** These are **ultra-short-acting** insulin analogs. They are designed to have a very rapid onset and a sharp, high peak (usually within 1 hour) to control postprandial (after-meal) glucose spikes. * **Lente Insulin (Option D):** This is an **intermediate-acting** insulin (a mixture of ultralente and semilente). Unlike glargine, it has a definite peak of action (usually 6–12 hours) and a shorter duration of action (approx. 18–24 hours). **High-Yield NEET-PG Pearls:** * **Other Peakless Analogs:** Insulin **detemir** and **degludec** are also considered peakless, with degludec having the longest half-life (>40 hours). * **Modification:** Glargine is created by replacing asparagine with glycine at position A21 and adding two arginine residues to the C-terminus of the B-chain. * **Clinical Note:** Because of its acidic pH, Insulin glargine **cannot be mixed** in the same syringe with other insulins, as this would alter its absorption profile.

Q: Which of the following is not an insulin analogue?

Actrapid. **Explanation:** The distinction between **Insulin Analogues** and **Human Insulin** is a high-yield topic for NEET-PG. Insulin analogues are developed by modifying the amino acid sequence of human insulin using recombinant DNA technology to alter its pharmacokinetic profile (onset and duration). **Why Actrapid is the correct answer:** **Actrapid** is a brand name for **Regular (Neutral) Human Insulin**. It is not an analogue; rather, it is identical in structure to the native human insulin molecule. It is classified as "Short-acting" insulin. Because it forms hexamers at the injection site, its absorption is delayed, leading to a peak effect in 2–3 hours. **Analysis of incorrect options (Analogues):** * **Insulin Lispro & Insulin Aspart:** These are **Rapid-acting analogues**. Lispro is created by switching Lysine and Proline at positions B28 and B29. Aspart involves replacing Proline with Aspartic acid at B28. These modifications prevent hexamer formation, allowing for faster absorption and "prandial" (mealtime) coverage. * **Insulin Glargine:** This is a **Long-acting (Basal) analogue**. It is modified to be soluble at acidic pH but precipitates at physiological pH in subcutaneous tissue. This results in a slow, "peakless" release lasting 24 hours. **High-Yield Clinical Pearls for NEET-PG:** * **Ultra-short acting:** Lispro, Aspart, Glulisine (Mnemonic: **L**ive **A**s **G**old). * **Ultra-long acting:** Degludec (longest half-life, >40 hours), Glargine, Detemir. * **Inhaled Insulin:** Afrezza (Rapid-acting powder). * **Drug of choice in DKA:** Intravenous Regular Insulin (Actrapid). * **Safe in pregnancy:** Regular insulin, Aspart, and Lispro are commonly used; Glargine is also now considered safe.

Q: Which of the following is an androgen receptor blocking drug?

Cyproterone acetate. **Explanation:** **Cyproterone acetate** is a potent synthetic steroid that acts as a competitive antagonist at the **androgen receptor**. By blocking the binding of dihydrotestosterone (DHT) and testosterone to their receptors, it inhibits androgenic effects in target tissues. Additionally, it has progestational activity which suppresses the secretion of gonadotropins (LH and FSH), further reducing testosterone production. It is clinically used in the management of hirsutism in females, precocious puberty in boys, and as palliative treatment for prostatic carcinoma. **Analysis of Incorrect Options:** * **Tamoxifen (Option A):** A Selective Estrogen Receptor Modulator (SERM). It acts as an estrogen antagonist in the breast (used in breast cancer) but as an agonist in the bone and endometrium. * **Mifepristone (Option C):** A potent **progesterone receptor antagonist** (used for medical abortion) and a glucocorticoid receptor antagonist (used in Cushing’s syndrome). * **Nalondrone (Option D):** Likely a distractor or misspelling of **Nandrolone**, which is an **anabolic steroid** (androgen agonist), not a blocker. **High-Yield Clinical Pearls for NEET-PG:** * **Other Androgen Receptor Blockers:** Flutamide, Bicalutamide (non-steroidal, used in prostate cancer), and Spironolactone (also blocks aldosterone receptors). * **5-alpha Reductase Inhibitors:** Finasteride and Dutasteride (prevent conversion of Testosterone to DHT; used in BPH and male pattern baldness). * **GnRH Analogues:** Leuprolide and Goserelin (cause medical castration via pituitary desensitization). * **Side Effect:** A common side effect of androgen blockers in males is **gynecomastia**.

Q: Which of the following is contraindicated in diabetics with Congestive Heart Failure?

Pioglitazone. **Explanation:** The correct answer is **Pioglitazone**. **1. Why Pioglitazone is Contraindicated:** Pioglitazone belongs to the **Thiazolidinedione (TZD)** class. Its primary mechanism involves activating the PPAR-gamma receptor, which leads to increased sodium and water reabsorption in the renal collecting ducts. This results in **fluid retention, peripheral edema, and plasma volume expansion** [1]. In patients with pre-existing Congestive Heart Failure (CHF), this volume overload can precipitate acute decompensation. According to clinical guidelines (NYHA Class III or IV), TZDs are strictly contraindicated in symptomatic heart failure. **2. Analysis of Incorrect Options:** * **Empagliflozin (SGLT2 Inhibitor):** Far from being contraindicated, these are now a **gold standard** treatment for patients with both Diabetes and CHF (HFrEF and HFpEF). They promote osmotic diuresis and natriuresis, significantly reducing heart failure hospitalizations. * **Metformin (Biguanide):** Historically avoided in HF due to fears of lactic acidosis; however, current guidelines state it is safe in stable CHF if renal function is preserved (eGFR >30 mL/min) [2]. * **Linagliptin (DPP-4 Inhibitor):** Most DPP-4 inhibitors are safe in CHF [1]. While *Saxagliptin* is associated with increased HF hospitalizations, Linagliptin has shown cardiovascular safety (CARMELINA trial) and is safe to use. **Clinical Pearls for NEET-PG:** * **SGLT2 inhibitors** (Empagliflozin, Dapagliflozin) are the drugs of choice for Diabetics with HF. * **Saxagliptin** is the specific DPP-4 inhibitor to avoid in HF (mnemonic: "S" for Saxagliptin, "S" for Stay away in HF). * **TZDs** (Pioglitazone) also increase the risk of **osteoporotic fractures** and are associated with a potential risk of **bladder cancer**.

Q: Tolvaptan is approved for use in which of the following conditions?

Hyponatremia. Explanation: **Tolvaptan** is a selective, oral **Vasopressin V2-receptor antagonist** (often referred to as an "Aquaretic"). By blocking the V2 receptors in the renal collecting ducts, it prevents the insertion of aquaporin-2 channels, thereby increasing the excretion of free water without significant loss of electrolytes [1]. **Why Hyponatremia is Correct:** Tolvaptan is specifically FDA-approved for the treatment of **clinically significant hypervolemic and euvolemic hyponatremia** (Serum Na <125 mEq/L). It is commonly used in conditions like **SIADH** (Syndrome of Inappropriate Antidiuretic Hormone secretion), Heart Failure, and Cirrhosis, where free water restriction has failed [1]. By promoting "aquaresis," it raises serum sodium levels. **Why Other Options are Incorrect:** * **A. Hypernatremia:** Tolvaptan would worsen hypernatremia by further increasing free water loss. * **B. Hyperkalemia:** Tolvaptan does not significantly affect potassium excretion; hyperkalemia is typically managed with insulin/dextrose, calcium gluconate, or potassium binders. * **C. Hypercupruria:** This refers to excess copper in urine (seen in Wilson’s disease), which is treated with chelating agents like Penicillamine or Trientine, not vaptans. **High-Yield Clinical Pearls for NEET-PG:** * **Black Box Warning:** Tolvaptan should be initiated only in a hospital setting to monitor the rate of sodium correction. Rapid correction can lead to **Osmotic Demyelination Syndrome (ODS)**. * **Hepatotoxicity:** Use is limited to 30 days due to the risk of liver injury. * **Other Vaptans:** **Conivaptan** is a non-selective (V1a and V2) antagonist administered intravenously. * **Other Indications:** Tolvaptan is also used to slow the progression of cyst formation in **Autosomal Dominant Polycystic Kidney Disease (ADPKD)**.

Q: What is a common side effect of thiazolidinediones?

Water retention with weight gain. ### Explanation **Thiazolidinediones (TZDs)**, such as Pioglitazone and Rosiglitazone, are PPAR-γ (Peroxisome Proliferator-Activated Receptor gamma) agonists. They act primarily by increasing insulin sensitivity in peripheral tissues (adipose, muscle, and liver). **Why Option C is Correct:** The most characteristic side effect of TZDs is **fluid retention (edema) and weight gain**. This occurs because PPAR-γ receptors are also expressed in the collecting ducts of the nephron. Activation of these receptors leads to increased sodium and water reabsorption (via ENaC channels). This fluid overload can precipitate or worsen **congestive heart failure (CHF)**, making it a major contraindication in patients with NYHA Class III or IV heart failure. **Analysis of Incorrect Options:** * **A. Dysgeusia:** This (metallic taste) is a classic side effect of **Metformin**, not TZDs. * **B. Hypoglycemia:** TZDs are "euglycemics." Since they enhance the action of endogenous insulin rather than increasing insulin secretion, they rarely cause hypoglycemia when used as monotherapy. * **D. Anemia:** While mild hemodilutional anemia can occur due to fluid retention, it is not as clinically hallmark or frequently tested as weight gain and edema. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** PPAR-γ is a nuclear receptor; TZDs increase the expression of **GLUT-4** and adiponectin. * **Bone Health:** TZDs are associated with an increased risk of **fractures** (especially in women) due to decreased osteoblast differentiation. * **Bladder Cancer:** Pioglitazone has a controversial but noted association with an increased risk of bladder cancer (avoid in patients with active or past history of bladder cancer). * **Hepatotoxicity:** Troglitazone (the first TZD) was withdrawn due to severe liver injury; monitoring LFTs is still recommended for current TZDs.

Q: All of the following are used to treat hypercalcemia, EXCEPT:

D-penicillamine. **Explanation:** Hypercalcemia is a critical metabolic emergency requiring agents that either decrease bone resorption, increase renal excretion, or decrease intestinal absorption of calcium. **Why D-penicillamine is the correct answer:** D-penicillamine is a **chelating agent** primarily used in the treatment of **Wilson’s disease** (to remove copper), cystinuria, and severe rheumatoid arthritis. It has no clinical role in the management of hypercalcemia. **Analysis of incorrect options (Agents used in Hypercalcemia):** * **Corticosteroids (Option B):** These are particularly effective in hypercalcemia associated with **sarcoidosis, vitamin D intoxication, and lymphomas**. They work by decreasing the intestinal absorption of calcium and inhibiting the expression of 1-alpha-hydroxylase. * **Bisphosphonates (Option C):** (e.g., Zoledronate, Pamidronate) These are the **drugs of choice** for malignancy-associated hypercalcemia. They act by inhibiting osteoclast activity, thereby reducing bone resorption. * **Mithramycin (Plicamycin) (Option D):** This is a cytotoxic antibiotic that inhibits osteoclast function. While effective for refractory hypercalcemia, its use is limited due to significant toxicity (nephrotoxicity and thrombocytopenia). **NEET-PG High-Yield Pearls:** * **Immediate Management:** The first step in severe hypercalcemia is always **aggressive IV hydration with Normal Saline**, followed by loop diuretics (Furosemide) to promote "calciuresis." * **Calcitonin:** Used for rapid reduction of calcium (works within hours) but is limited by **tachyphylaxis** (diminishing effect after 48 hours). * **Cinacalcet:** A calcimimetic used specifically for hypercalcemia in secondary hyperparathyroidism or parathyroid carcinoma. * **Denosumab:** A RANKL inhibitor used when bisphosphonates are contraindicated or ineffective.

Question 1

Finasteride has efficacy in the prevention of male pattern baldness by virtue of its ability to:

Accepted Answer

Reduce the production of DHT

Answer

Competitively antagonize androgen receptors

Answer

Decrease the release of gonadotropins

Answer

Inhibit the synthesis of testosterone

Question 2

Which among the following is also called "peakless" insulin analog?

Accepted Answer

Insulin glargine

Answer

Insulin lispro

Answer

Insulin aspart

Answer

Lente Insulin

Question 3

Which of the following is not an insulin analogue?

Accepted Answer

Actrapid

Answer

Insulin glargine

Answer

Insulin lispro

Answer

Insulin aspart

Question 4

Which of the following is an androgen receptor blocking drug?

Accepted Answer

Cyproterone acetate

Answer

Tamoxifen

Answer

Mifepristone

Answer

Nalondrone

Question 5

Which of the following is contraindicated in diabetics with Congestive Heart Failure?

Accepted Answer

Pioglitazone

Answer

Empagliflozin

Answer

Metformin

Answer

Linagliptin

Question 6

Tolvaptan is approved for use in which of the following conditions?

Accepted Answer

Hyponatremia

Answer

Hypernatremia

Answer

Hyperkalemia

Answer

Hypercupruria

Question 7

What is a common side effect of thiazolidinediones?

Accepted Answer

Water retention with weight gain

Answer

Dysgeusia

Answer

Hypoglycemia

Answer

Anemia

Question 8

All of the following are used to treat hypercalcemia, EXCEPT:

Accepted Answer

D-penicillamine

Answer

Corticosteroid

Answer

Bisphosphonate

Answer

Mithramycin

Question 9

Which of the following has the least mineralocorticoid activity?

Accepted Answer

Methylprednisolone

Answer

Cortisol

Answer

Prednisolone

Answer

Fludrocortisone

Question 10

In the treatment of congenital adrenal hyperplasia due to lack of 21 β–hydroxylase, what is the purpose of administering a synthetic glucocorticoid?

Accepted Answer

Suppression of ACTH secretion

Answer

Inhibition of aldosterone synthesis

Answer

Prevention of hypoglycemia

Answer

Recovery of normal immune function

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?